Tianda Pharmaceuticals Limited provided consolidated earnings guidance for the current year from 1 January 2023 to 31 December 2023. The Group's unaudited consolidated management accounts for the Current Year, due to (1) an increase in both the revenue and gross profit of the Group compared with the Previous Period, (2) reduction in one-off expenses, and (3) reduction in research and development expenses charged to profit and loss account, it is expected the loss for the Current Year would be reduced by over HKD 15 million from HKD 44.2 million in the Previous Period.